Last reviewed · How we verify
V118
At a glance
| Generic name | V118 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of V118E in Healthy Participants (V118E-003) (PHASE1)
- A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) (PHASE1)
- Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V118 CI brief — competitive landscape report
- V118 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI